Pfizer COVID-19 Pill Does Not Provide Significant Benefit in Patients Under 65: Study

Paxlovid, a Pfizer COVID-19 pill, manufactured in Ascoli, Italy, in this undated handout photograph. Pfizer via Reuters

Pfizer’s COVID-19 pill helps reduce COVID-19 hospitalizations and deaths in the elderly but provides no strong benefit for those under 65, according to a new study.

Researchers in Israel gleaned data from Clalit Health Services, a health care organization that covers over half of the entire population in the country.